The Institute of Cancer Research

(IN BRIEF) AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has gained approval from the US Food and Drug Administration (FDA) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer possessing specific … Read the full press release →

(IN BRIEF) Aviva and mixed-use developer Socius have been selected as the preferred bidders for the advancement of the London Cancer Hub (LCH), a world-leading district dedicated to cancer research and treatment in Sutton, London. The partnership will collaborate with … Read the full press release →

(IN BRIEF) AstraZeneca’s new drug application (NDA) for capivasertib, in combination with Faslodex, has been accepted and granted Priority Review by the US FDA for the treatment of advanced breast cancer. The NDA is being reviewed under Project Orbis, which … Read the full press release →